HomeREGULATORY
REGULATORY

Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
(Aug.23.2017)

The health ministry’s key reimbursement panel on August 23 gave its blessing to Biogen Japan’s spinal muscular atrophy (SMA) treatment Spinraza (nusinersen), with an NHI price of 9.32 million yen, and six other drugs for their reimbursement listing on August 30 ...
(LOG IN FOR FULL STORY)

News Calendar